Drug Profile


Alternative Names: Belsomra; MK-4305

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Azepines; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Insomnia

Most Recent Events

  • 01 May 2016 Merck Sharp & Dohme initiates enrolment in a phase III trial for Insomnia in USA (PO) (NCT02750306)
  • 21 Apr 2016 Merck Sharp & Dohme plans a phase III trial for Insomnia in USA (PO) (NCT02750306)
  • 15 Apr 2016 Efficacy data from two pooled trials in Insomnia released by Merck & Co
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top